Concepedia

Publication | Closed Access

Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents

DOI

228

Citations

32

References

2011

Year

Chirag P. Shah, Sunir J. Garg, J.F. Vander, Gary C. Brown, Richard Kaiser, Julia A. Haller
Ophthalmology

References

YearCitations

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier,

New England Journal of Medicine

2006

5.8K

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels,

New England Journal of Medicine

2006

3.5K

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Michael J. Elman, Lloyd Paul Aiello, Roy W. Beck,

Ophthalmology

2010

1.4K

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

David M. Brown, Mark Michels, Peter K. Kaiser,

Ophthalmology

2008

1.3K

Results of the Endophthalmitis Vitrectomy Study

Archives of Ophthalmology

1995

1.3K

Ranibizumab for Macular Edema following Central Retinal Vein Occlusion

David M. Brown, Peter A. Campochiaro, Rishi P. Singh,

Ophthalmology

2010

1.1K

Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion

Peter A. Campochiaro, Jeffrey S. Heier, Leonard Feiner,

Ophthalmology

2010

798

Prophylaxis of Endophthalmitis with Topical Povidone-iodine

Mark G. Speaker, Jerry Menikoff

Ophthalmology

1991

571

ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Diane Brown, Peter K. Kaiser, Mark Michels,

2006

382

Bleb-related Endophthalmitis after Trabeculectomy with Mitomycin C

Eve J. Higginbotham, Rachel Stevens, David C. Musch,

Ophthalmology

1996

335

Page 1